Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Rate Poster

Immuno Delivery (Focus Group - ID)

(239) LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment

Introduction: SARS-CoV-2 vaccines, including Pfizer/BioNTech’s BNT162b2 and Moderna’s mRNA-1273, encapsulate mRNA encoding spike proteins to induce spike-specific antibody and T-cell immunity (1, 2). With a significant portion of the global population immunized, this pre-existing T-cell immunity offers an opportunity to address challenges in cancer immunotherapy. Spike epitope-loaded single-chain trimer (SCT) MHC I molecules have shown to induce antigen-specific immune responses, and the delivery of those by lipid nanoparticles (LNP) will enable robust anti-tumor responses in vaccinated individuals (3, 4).

Learning Objectives:

  • Learn to formulate and optimize lipid nanoparticles (LNPs) for efficient and safe mRNA delivery.
  • Examine spike-specific T-cell immunity induction by vaccine and reactivation by SCT MHC I molecules.
  • Assess the potential of LNP-RNA antigen presentation to repurpose SARS-CoV-2 T-cell immunity.